The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk.
 
Edward C. Li
Employment - Sandoz
Honoraria - Sandoz
Consulting or Advisory Role - New Century Health (Inst)
Speakers' Bureau - Pfizer
 
Dylan Mezzio
Employment - Xcenda
Consulting or Advisory Role - Xcenda
Research Funding - Xcenda
Travel, Accommodations, Expenses - Xcenda
 
Andrew Spargo
Employment - Xcenda
Consulting or Advisory Role - Xcenda
Research Funding - Xcenda
Travel, Accommodations, Expenses - Xcenda
 
Kimberley J. Campbell
Employment - Sandoz-Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Sandoz-Novartis
 
Gary H. Lyman
Consulting or Advisory Role - BeyondSpring Pharmaceuticals; bioTheranostics; Daiichi Sankyo; G1 Therapeutics; invitae; Mylan; Partners Healthcare; Samsung Bioepis; Sandoz-Novartis; Spectrum Pharmaceuticals
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Bayer